The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
FDA clears FT538, the first CRISPR-edited, iPSC-derived cell therapy, for investigation as a new drug in AML and MM
On May 20, 2020, the U.S. Food & Drug Administration (FDA) cleared FT538, the first CRISPR-edited, induced pluripotent stem cell...
May 26, 2020
Pretransplant FLT3/ITD status as a prognostic marker for outcome in FLT3-mutated AML
Internal tandem duplication (ITD) of the juxtamembrane domain of the FMS-like tyrosine kinase-3 (FLT3/ITD) gene is a common mutation detected in 30% of patients with...
May 25, 2020
The effect of CD34+ cell dose on responses to haploidentical allo-HSCT: Results from a retrospective analysis
The graft cell dose following allogenic hematopoietic stem cell transplantation (allo-HSCT) has been suggested to influence patient outcome....
May 20, 2020
Gert Ossenkoppele
" The AML Hub disseminates the most up-to-date information on AML for academic researchers and treating clinicians worldwide, to help improve their understanding of the latest advances in terms of research, biology, and treatment options. "
Your opinion matters